These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25970013)

  • 1. Ponatinib (Iclusig) for CML and Ph+ ALL.
    Med Lett Drugs Ther; 2013 Sep; 55(1424):71-2. PubMed ID: 25970013
    [No Abstract]   [Full Text] [Related]  

  • 2. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Narayanan V; Pollyea DA; Gutman JA; Jimeno A
    Drugs Today (Barc); 2013 Apr; 49(4):261-9. PubMed ID: 23616953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Hoy SM
    Drugs; 2014 May; 74(7):793-806. PubMed ID: 24807266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ponatinib in the therapy of chronic myeloid leukemia.
    Poch Martell M; Sibai H; Deotare U; Lipton JH
    Expert Rev Hematol; 2016 Oct; 9(10):923-32. PubMed ID: 27590270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
    Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
    Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
    [No Abstract]   [Full Text] [Related]  

  • 7. Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.
    Shomali W; Redmond C; Bogati S; Zimmerman C; Visconte V; Tabarroki A; Kalaycio M; Tiu RV
    Leuk Lymphoma; 2016; 57(1):193-5. PubMed ID: 25942382
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponatinib superior to imatinib in Ph
    Sidaway P
    Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38806653
    [No Abstract]   [Full Text] [Related]  

  • 10. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.
    Heiblig M; Rea D; Chrétien ML; Charbonnier A; Rousselot P; Coiteux V; Escoffre-Barbe M; Dubruille V; Huguet F; Cayssials E; Hermet E; Guerci-Bresler A; Amé S; Sackmann-Sala L; Roy L; Sobh M; Morisset S; Etienne G; Nicolini FE
    Exp Hematol; 2018 Nov; 67():41-48. PubMed ID: 30195076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells.
    Okabe S; Tanaka Y; Moriyama M; Gotoh A
    Leuk Lymphoma; 2020 Jan; 61(1):237-239. PubMed ID: 31502898
    [No Abstract]   [Full Text] [Related]  

  • 12. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
    Korfi K; Mandal A; Furney SJ; Wiseman D; Somervaille TCP; Marais R
    Ann Oncol; 2015 Jun; 26(6):1180-1187. PubMed ID: 25712455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management.
    Saussele S; Haverkamp W; Lang F; Koschmieder S; Kiani A; Jentsch-Ullrich K; Stegelmann F; Pfeifer H; La Rosée P; Goekbuget N; Rieger C; Waller CF; Franke GN; le Coutre P; Kirchmair R; Junghanss C
    Acta Haematol; 2020; 143(3):217-231. PubMed ID: 31590170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig
    Yoshida T; Leen Liew E; Ota M; Nakayama H; Yanagihara Y; Nakamura Y; Seriu T; Kamishohara M
    Nihon Yakurigaku Zasshi; 2017; 150(1):54-61. PubMed ID: 28690276
    [No Abstract]   [Full Text] [Related]  

  • 15. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
    Boo YL; Liam CCK; Toh SG; Lim SM
    Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-life Experience With Ponatinib in Chronic Myeloid Leukemia: A Multicenter Observational Study.
    Shacham-Abulafia A; Raanani P; Lavie D; Volchek Y; Ram R; Helman I; Shargian L; Gourevitch A; Chubar E; Ratzon R; Rozovski U
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e295-e301. PubMed ID: 29773429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In brief: ponatinib (Inclusig) returns.
    Med Lett Drugs Ther; 2014 Jan; 56(1434):8. PubMed ID: 24457561
    [No Abstract]   [Full Text] [Related]  

  • 19. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
    Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
    Cortes JE; Kim DW; Pinilla-Ibarz J; le Coutre P; Paquette R; Chuah C; Nicolini FE; Apperley JF; Khoury HJ; Talpaz M; DiPersio J; DeAngelo DJ; Abruzzese E; Rea D; Baccarani M; Müller MC; Gambacorti-Passerini C; Wong S; Lustgarten S; Rivera VM; Clackson T; Turner CD; Haluska FG; Guilhot F; Deininger MW; Hochhaus A; Hughes T; Goldman JM; Shah NP; Kantarjian H;
    N Engl J Med; 2013 Nov; 369(19):1783-96. PubMed ID: 24180494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.